Effect of TRK-100, a prostacyclin analogue, on endotoxin-induced enhancement of blood coagulation in rats.
TRK-100 (0.03, 0.1 and 0.3 mg/kg, p.o.), a chemically stable analogue of prostacyclin, dose-dependently prevented blood coagulation and glomerular fibrin deposition which were enhanced by 4 hr infusion of endotoxin (100 mg/kg) in rats. In addition, TRK-100 suppressed the generation of endotoxin-induced tissue thromboplastin like activity in cultured human endothelial cells.
Sakai
A
A
Central Research Institute, Kaken Pharmaceutical Co., Ltd., Kyoto, Japan.
Hori
T
T
Okuda
T
T
Matsubara
T
T
Saitoh
K
K
Yajima
M
M
Nishio
S
S
D000284:Administration, Oral; D000818:Animals; D001777:Blood Coagulation / Q000187:drug effects*; D004305:Dose-Response Relationship, Drug; D004731:Endotoxins / Q000494:pharmacology*; D011464:Epoprostenol / Q000494:pharmacology* / Q000031:analogs & derivatives; D006801:Humans; D008297:Male; D010975:Platelet Aggregation Inhibitors / Q000494:pharmacology*; D051381:Rats; D011919:Rats, Inbred Strains; D013925:Thromboplastin / Q000502:physiology
D004731:Endotoxins; D010975:Platelet Aggregation Inhibitors; C048081:beraprost; D013925:Thromboplastin; D011464:Epoprostenol